ESLT:TASEElbit Systems Ltd Analysis
Data as of 2026-03-11 - not real-time
$877.12
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Elbit Systems trades at $877.12, comfortably above its 20‑day ($774.72), 50‑day ($716.37) and 200‑day ($532.88) simple moving averages, while the 14‑day RSI sits at 68.6 and the MACD line remains bullish with a positive histogram, indicating strong short‑term momentum and an increasing volume trend. However, the stock’s valuation metrics are extreme: a trailing P/E of 89.3 versus an industry average of 29.4, a price‑to‑book of 10.1, and a DCF‑derived fair value of only $231.9, implying a downside of roughly 35% from current levels.
Recent contract wins totaling approximately $435 million (including a $228 million follow‑on Iron Fist APS deal) provide a clear catalyst for revenue growth, yet the company’s modest profit margin (5.9%), low dividend yield (0.34%) and modest payout ratio (22%) offer limited upside. Combined with high 30‑day volatility (≈47%) but a very low beta (0.23), the stock presents a classic case of strong technicals and news‑driven optimism against a fundamentally overvalued backdrop.
Recent contract wins totaling approximately $435 million (including a $228 million follow‑on Iron Fist APS deal) provide a clear catalyst for revenue growth, yet the company’s modest profit margin (5.9%), low dividend yield (0.34%) and modest payout ratio (22%) offer limited upside. Combined with high 30‑day volatility (≈47%) but a very low beta (0.23), the stock presents a classic case of strong technicals and news‑driven optimism against a fundamentally overvalued backdrop.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish technical indicators (price above SMAs, MACD bullish)
- Recent high‑value contract awards boosting near‑term revenue
- Extreme valuation metrics limiting upside potential
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustained contract pipeline over the next 3‑6 years
- Persistently high P/E and price‑to‑book ratios
- Moderate volatility with low systematic risk (beta)
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- DCF fair value far below current market price
- Low dividend yield and modest payout ratio
- High valuation multiples relative to peers and industry
Key Metrics & Analysis
Financial Health
Revenue Growth11.90%
Profit Margin5.91%
P/E Ratio89.3
ROE12.90%
ROA3.47%
Debt/Equity26.61
P/B Ratio10.1
Op. Cash Flow$913.1M
Free Cash Flow$484.0M
Industry P/E29.4
Technical Analysis
TrendBullish
RSI68.6
Support$651.86
Resistance$960.00
MA 20$774.72
MA 50$716.37
MA 200$532.88
MACDBullish
VolumeIncreasing
Fear & Greed Index76.91
Valuation
Fair Value$231.91
Target Price$566.50
Upside/Downside-35.41%
GradeOvervalued
TypeGrowth
Dividend Yield0.34%
Risk Assessment
Beta0.23
Volatility46.91%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.